Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aims: Erythropoiesis‐stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKD patients. To investigate alternative therapies to erythropoiesis‐stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients. Methods: Preclinical in vitro/vivo data and clinical data in healthy subjects and CKD patients were used to illustrate the translation of pharmacological properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin–ferroportin pathway. Results: LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin saturation levels and increased hepcidin in monkeys and humans. In CKD patients, LY2928057 led to slower haemoglobin decline and reduction in ferritin (compared to placebo). Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46–2.68] and 1.36 [1.22–1.51] fold‐relative to baseline following LY2928057 600 mg and LY311593 150 mg respectively in CKD patients. LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin saturation and decreases in hepcidin preclinically and clinically. In CKD patients, LY3113593 produced an increase in haemoglobin and reduction in ferritin (compared to placebo). Conclusion: LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical‐to‐clinical development. Such interventions may lead to new CKD anaemia treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319 · cited 1×
“IL‐6 induces hepcidin through the JAK/STAT3 pathway.(23) A number of preclinical studies demonstrated that BMP6 and IL‐6 play roles in regulating hepcidin expression.”
BackgroundGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · cited 1×
“A number of preclinical studies demonstrated that BMP6 and IL‐6 play roles in regulating hepcidin expression.(14,20,21,24,25) The central roles of BMP6, IL‐6, hepcidin and ferroportin in iron sequestration found in anaemia of CKD and AI, allow for the”
BackgroundGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
Interleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983
Drakesmith, H., Nemeth, E., & Ganz, T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.006 · Cited by 638
A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression
Wang, R.-H., Li, C., Xu, X., Zheng, Y., Xiao, C., Zerfas, P., Cooperman, S., Eckhaus, M., Rouault, T., Mishra, L., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.10.010 · Cited by 614
Research works printed but not linked: 30
- 10.7326/0003-4819-153-1-201007060-00252 · DOI · Paper page
- 10.1056/NEJMoa062276 · DOI · Paper page
- 10.2215/CJN.02380607 · DOI
- 10.1080/14656566.2017.1323872 · DOI
- 10.1681/ASN.2014090922 · DOI
- 10.1097/00002480-199407000-00122 · DOI
- 10.1371/journal.pone.0123072 · DOI
- 10.3324/haematol.2009.014399 · DOI · Paper page
- 10.1126/science.1104742 · DOI · Paper page
- 10.1002/ajh.23110 · DOI · Paper page
- 10.1016/j.bbagen.2008.08.006 · DOI · Paper page
- 10.3324/haematol.2011.048926 · DOI · Paper page
- 10.1182/blood-2011-03-339952 · DOI · Paper page
- 10.1111/bph.13883 · DOI · Paper page
- 10.1182/blood-2006-11-057471 · DOI · Paper page
- 10.1093/nar/gkx1121 · DOI · Paper page
- 10.1111/bph.13877 · DOI · Paper page
- 10.1016/S0301-472X(01)00723-8 · DOI
- 10.1186/s13045-017-0427-x · DOI · Paper page
- 10.1208/s12248-010-9222-0 · DOI
- 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8 · DOI · Paper page
- 10.1371/journal.pcbi.1003421 · DOI
- 10.1038/ki.2009.503 · DOI · Paper page
- 10.1016/j.bcmd.2005.04.005 · DOI
- 10.1053/j.ajkd.2015.12.020 · DOI · Paper page
- 10.1053/ajkd.2001.22433 · DOI · Paper page
- 10.1007/s10157-010-0288-x · doi:10.1007/s10157-010-0288-x
- 10.1038/ki.2014.114 · DOI · Paper page
- 10.1681/ASN.2015010052 · DOI
- 10.1093/ndt/gfs488 · DOI
Cited by
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Iron metabolism: pathophysiology and pharmacology
Roemhild, K., von Maltzahn, F., Weiskirchen, R., Knüchel, R., von Stillfried, S., & Lammers, T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.05.001 · Cited by 302
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Metadata
- Authors
- Sheetz, M., Barrington, P., Callies, S., Berg, P. H., McColm, J., Marbury, T., Decker, B., Dyas, G. L., Truhlar, S. M. E., Benschop, R., Leung, D., Berg, J., & Witcher, D. R.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2019-03-04
- Volume
- 85
- Issue
- 5
- Pages
- 935-948
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2913829274
- Cited by
- 76
- References
- 21
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.